208 related articles for article (PubMed ID: 29667086)
1. Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study.
Hempel JM; Brendle C; Bender B; Bier G; Skardelly M; Gepfner-Tuma I; Eckert F; Ernemann U; Schittenhelm J
J Neurooncol; 2018 Sep; 139(2):373-381. PubMed ID: 29667086
[TBL] [Abstract][Full Text] [Related]
2. Diffusion kurtosis imaging histogram parameter metrics predicting survival in integrated molecular subtypes of diffuse glioma: An observational cohort study.
Hempel JM; Brendle C; Bender B; Bier G; Kraus MS; Skardelly M; Richter H; Eckert F; Schittenhelm J; Ernemann U; Klose U
Eur J Radiol; 2019 Mar; 112():144-152. PubMed ID: 30777204
[TBL] [Abstract][Full Text] [Related]
3. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
5. In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
Hempel JM; Bisdas S; Schittenhelm J; Brendle C; Bender B; Wassmann H; Skardelly M; Tabatabai G; Vega SC; Ernemann U; Klose U
J Neurooncol; 2017 Jan; 131(1):93-101. PubMed ID: 27604789
[TBL] [Abstract][Full Text] [Related]
6. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
7. Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Wang X; Li F; Wang D; Zeng Q
Eur J Radiol; 2020 Jul; 128():108985. PubMed ID: 32361603
[TBL] [Abstract][Full Text] [Related]
8. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
9. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
10. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
11. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Hilario A; Hernandez-Lain A; Sepulveda JM; Lagares A; Perez-Nuñez A; Ramos A
Neurocirugia (Astur : Engl Ed); 2019; 30(1):11-18. PubMed ID: 30143443
[TBL] [Abstract][Full Text] [Related]
12. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
14. Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival.
Weng W; Chen X; Gong S; Guo L; Zhang X
Neurol Res; 2018 Nov; 40(11):917-922. PubMed ID: 30074469
[TBL] [Abstract][Full Text] [Related]
15. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
16. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
17. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma.
Lopci E; Riva M; Olivari L; Raneri F; Soffietti R; Piccardo A; Bizzi A; Navarria P; Ascolese AM; Rudà R; Fernandes B; Pessina F; Grimaldi M; Simonelli M; Rossi M; Alfieri T; Zucali PA; Scorsetti M; Bello L; Chiti A
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1155-1164. PubMed ID: 28110346
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
